[Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy].
OBJECTIVE
To observe the changes in urine albumin (UALB), von Willebrand factor (vWF) and platelet-activating factor (PAF) in different courses of type 2 diabetes.


METHODS
Levels of UALB, vWF and PAF were determined in 30 type 2 diabetic nephropathy patients(group A), type 2 diabetic patients without DNP(group B, n=30), patients with impaired glucose tolerance (group C, n=30), the first-degree relatives of type 2 diabetic patients with normal glucose tolerance(group D, n=30) and 30 normal glucose tolerance subjects without family history of type 2 diabetes(group E).


RESULTS
UALB and PAF contents were significantly higher in group A than in the other groups (P<0.01), while between the latter 4 groups, the contents showed no significant differences (P>0.05). Serum vWF level was significantly higher in group A than those in the other groups (P<0.05).


CONCLUSIONS
Renal dysfunction and platelet activation are present in type 2 diabetes with microvascular complications, and the synchronized changes between renal dysfunction and platelet activation indicate the involvement of elevated PAF in vascular injury.
Fang
Yong-hong
YH
Second People's Hospital of Foshan City, Foshan 528000, China.
Zhang
Ji-ping
JP
Zhou
Shao-xiong
SX
Zheng
Ju-fen
JF
Yu
Yong-wei
YW
Yan
Shi-gang
SG
Fan
Wen-kui
WK
Cheng
Yue-song
YS
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000378:metabolism*; D014841:von Willebrand Factor / Q000378:metabolism*
D010972:Platelet Activating Factor; D014841:von Willebrand Factor